Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
licensing
Pharma
Novartis tasks Lindy to turn biologics into at-home injectables
In a deal worth up to $954 million, Novartis will use Lindy’s suspension technology to design self-administered drugs against multiple targets.
Angus Liu
Aug 28, 2024 10:18am
Eisai, Takeda, BIOSECURE Act—Fierce Pharma Asia
May 17, 2024 8:30am
Novartis returns PD-1 to BeiGene in another cancer drug divorce
Sep 19, 2023 9:10am
Otsuka, Astellas, Exelixis and Insilico—Fierce Pharma Asia
Sep 15, 2023 9:00am
Arbitration win over J&J gives Alkermes a $425M boost
Jun 6, 2023 3:23pm
Neurocrine gives up on Parkinson's drug Ongentys
May 3, 2023 10:55am
